Type D personality predicts death or myocardial infarction after bare metal stent or sirolimus-eluting stent implantation — Susanne S. Pedersen (2004) | RDL Network
Type D personality predicts death or myocardial infarction after bare metal stent or sirolimus-eluting stent implantation
Journal of the American College of Cardiology 44(5): 997-1001
Article 2004 English
Authors
SP
Susanne S. Pedersen
PL
Pedro A. Lemos
PV
Priya R. van Vooren
Abstract
1 min read
Objectives
We investigated the effect of Type D personality on the occurrence of adverse events at nine months in patients with ischemic heart disease (IHD) after percutaneous coronary intervention (PCI) with sirolimus-eluting stents (SESs) or bare stents. Type D patients experience increased negative emotions and tend not to express these emotions in social interactions.
Background
The SES is a new advent in interventional cardiology that reduces the restenosis rate and the risk of a major adverse cardiac event, but the SES has not been shown to confer any benefits on death or myocardial infarction (MI).
Methods
Consecutive patients with IHD (n = 875) enrolled in the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry completed the Type D Personality Scale (DS14) six months after PCI. The end point was a composite of death and MI. Events occurring before administration of the DS14 were excluded from analyses.
Results
At nine months' follow-up, there were 20 events. Type D patients were at a cumulative increased risk of adverse outcome compared with non-Type D patients: 5.6% versus 1.3% (p < 0.002). Type D personality (odds ratio [OR] 5.31; 95% confidence interval [CI] 2.06 to 13.66) remained an independent predictor of adverse outcome adjusting for all other variables, including SES versus bare-stent implantation.
Conclusions
Type D personality was an independent predictor of adverse events in patients optimally treated with the latest advent in interventional cardiology. The DS14 could be used as a screening instrument in routine clinical practice to optimize risk stratification in IHD patients.
Pedro A. Lemos, Patrick W. Serruys, Ron T. van Domburg, Francesco Saia, Chourmouzios A. Arampatzis, Angela Hoye, Muzaffer Değertekin, Kengo Tanabe, Joost Daemen, Tommy K.K. Liu, Eugène McFadden, Georgios Sianos, Sjoerd H. Hofma, Pieter C. Smits, Willem J. van der Giessen, Pim J. de Feyter
Pedro A. Lemos, Chi‐Hang Lee, Muzaffer Değertekin, Francesco Saia, Kengo Tanabe, Chourmouzios A. Arampatzis, Angela Hoye, Marco van Duuren, Giorgios Sianos, Pieter C. Smits, Pim de Feyter, Willem J. van der Giessen, Ron T. van Domburg, Patrick W. Serruys
Francesco Saia, Pedro A. Lemos, Chi‐Hang Lee, Chourmouzios A. Arampatzis, Angela Hoye, Muzaffer Değertekin, Kengo Tanabe, Georgios Sianos, Pieter C. Smits, Eugène McFadden, Sjoerd H. Hofma, Willem J. van der Giessen, Pim J. de Feyter, Ron T. van Domburg, Patrick W. Serruys
Pedro A. Lemos, Francesco Saia, Sjoerd H. Hofma, Joost Daemen, Andrew T.L. Ong, Chourmouzios A. Arampatzis, Angela Hoye, Eugène McFadden, Georgios Sianos, Pieter C. Smits, Willem J. van der Giessen, Pim de Feyter, Ron T. van Domburg, Patrick W. Serruys
Discussion(0)
No comments yet. Be the first to comment.